Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Dec;134(7):1516-22.
doi: 10.1038/sj.bjp.0704398.

Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats

Affiliations

Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats

J Kyselovic et al. Br J Pharmacol. 2001 Dec.

Abstract

1. Calcium channel blockers (CCBs) are anti-hypertensive drugs that are usually considered to act mainly as vasodilators. We investigated the relation between the reduction of blood pressure evoked by two long-acting CCBs and their protective effect against cardiac and renal damage in salt-loaded stroke-prone spontaneously hypertensive rats (SHRSP). 2. SHRSP were exposed to high dietary salt intake (1% NaCl in drinking solution) from 8 to 14 weeks of age, with or without amlodipine or lacidipine at three dosage regimens producing similar effects on blood pressure. 3. The lowest dosages of both drugs had non-significant effects on blood pressure but inhibited the paradoxical increases in plasma renin activity (PRA) and in renin mRNA in kidney that were found in salt-loaded SHRSP. The lowest dosage of lacidipine (but not of amlodipine) restored the physiological downregulation of renin production by high salt and reduced left ventricular hypertrophy and mRNA levels of atrial natriuretic factor and transforming growth factor-beta1. 4. The intermediate dosages reduced blood pressure and PRA in a comparable manner, but cardiac hypertrophy was more reduced by lacidipine than by amlodipine. 5. Although the highest doses exhibited a further action on blood pressure, they had no additional effect on cardiac hypertrophy, and they increased PRA and kidney levels of renin mRNA even more than in the absence of drug treatment. 6. We conclude that reduction of blood pressure is not the sole mechanism involved in the prevention of cardiac remodelling by CCBs, and that protection against kidney damage and excessive renin production by low and intermediate dosages of these drugs contributes to their beneficial cardiovascular effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relation between relative left ventricular mass and systolic blood pressure in salt-loaded SHRSP. S, salt-loaded SHRSP; A1.5, amlodipine 1.5 mg kg−1; A5, amlodipine 5 mg kg−1; A15, amlodipine 15 mg kg−1; L0.3, lacidipine 0.3 mg kg−1; L1, lacidipine 1 mg kg−1; L3, lacidipine 3 mg kg−1.
Figure 2
Figure 2
Northern analysis of mRNA levels in left ventricular tissue: typical autoradiograms. Blots were sequentially hybridized with 32P-labelled probes for collagen type I, TGF-β1, skeletal α-actin, ANF and GAPDH mRNA, as described in Methods. One per cent NaCl refers to salt given (+) or not given (−) in drinking water (see Methods). Drug doses are expressed in mg kg−1 day−1. mRNA size is given on the right.
Figure 3
Figure 3
Northern analysis of mRNA levels in left ventricular tissue. Data were corrected for GAPDH mRNA levels and normalized with respect to salt-loaded SHRSP (S). W, control SHRSP; A1.5, amlodipine 1.5 mg kg−1; A5, amlodipine 5 mg kg−1; A15, amlodipine 15 mg kg−1; L0.3, lacidipine 0.3 mg kg−1; L1, lacidipine 1 mg kg−1; L3, lacidipine 3 mg kg−1. Data are mean±s.e.mean of at least five rats (*P<0.05; **P<0.01; ***P<0.001).
Figure 4
Figure 4
Plasma renin activity and Northern analysis of mRNA levels in kidney tissue. mRNA levels were corrected for GAPDH mRNA levels and normalized with respect to salt-loaded SHRSP (S). W, control SHRSP; A1.5, amlodipine 1.5 mg kg−1; A5, amlodipine 5 mg kg−1; A15, amlodipine 15 mg kg−1; L0.3, lacidipine 0.3 mg kg−1; L1, lacidipine 1 mg kg−1; L3, lacidipine 3 mg kg−1. Data are mean±s.e.mean of at least five rats (**P<0.01 vs S; ***P<0.001 vs S; §P<0.05 vs W).
Figure 5
Figure 5
Northern analysis of mRNA levels in kidney tissue: typical autoradiograms. Blots were sequentially hybridized with 32P-labelled probes for renin, TGF-β1 and GAPDH mRNA, as described in Methods. One per cent NaCl refers to salt given (+) or not given (−) in drinking water (see Methods). Drug doses are expressed in mg kg−1 day−1. mRNA size is given on the right.

References

    1. BORDER W.A., NOBLE N.A. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 1998;31:181–188. - PubMed
    1. CAMPBELL S.E., TUREK Z., RAKUSAN K., KAZDA S. Cardiac structural remodelling after treatment of spontaneously hypertensive rats with nifedipine or nisoldipine. Cardiovasc. Res. 1993;27:1350–1358. - PubMed
    1. COMINACINI L., GARBIN U., FRATTA PASINI A., PAULON T., DAVOLI A., CAMPAGNOLA M., MARCHI E., PASTORINO A.M., GAVIRAGHI G., LO CASCIO V. Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J. Hypertens. 1997;15:1633–1640. - PubMed
    1. CRESPI F., VECCHIATO E., LAZZARINI C., GAVIRAGHI G. Electrochemical evidence that lacidipine stimulates release of nitrogen monoxide in rat aorta. Neurosci. Lett. 2001;298:171–174. - PubMed
    1. CRISTOFORI P., MICHELI D., TERRON A., GAVIRAGHI G. Lacidipine: experimental evidence of vasculoprotective properties. J. Cardiovasc. Pharmacol. 1994;23:S90–S93. - PubMed

Publication types

MeSH terms